1. ¹Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
2. ²Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, NC, USA

Correspondence: Dr MA Nader, Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Boulevard, 546 NRC, Winston-Salem, NC 27157-1083, USA. Tel: +1 336 713 7172; Fax: +1 336 713 7180; E-mail: mnader@wfubmc.edu

Received 14 July 2007; Revised 5 December 2007; Accepted 15 December 2007; Published online 6 February 2008.

Abstract

Sex differences have been reported in a variety of affective and neurodegenerative disorders that involve dysfunctional dopamine (DA) neurotransmission. In addition, there is evidence for differences in sensitivity to the abuse-related effects of psychostimulants across the menstrual cycle which may result from effects of ovarian hormones on DA function. The goal of the present study was to extend previous work examining menstrual cycle-related changes in DA D2 receptor availability in humans to drug-naive female cynomolgus monkeys (n=7) using the selective D2-like receptor ligand [¹⁸F]fluoroclebopride (FCP) and a high-resolution microPET P4 scanner. Menstrual cycle phase was characterized by daily vaginal swabs and measurements of serum progesterone levels. PET studies were conducted once during the luteal phase and once during the follicular phase. Regions of interest in the caudate nucleus, putamen, and cerebellum were defined on coregistered MRIs. Distribution volumes were calculated for FCP in each structure and the distribution volume ratio (DVR) for both brain regions relative to the cerebellum was used as a measure of D2 receptor availability. FCP DVRs were significantly higher in the luteal phase compared to the follicular phase in both the caudate nucleus (11.7% difference, p=0.02) and putamen (11.6% difference, p=0.03). These findings extend earlier work in humans and suggest that changes in DA receptor availability may be involved in the variation in symptoms of various neuropsychiatric disorders across the menstrual cycle, including differences in sensitivity to the abuse-related effects of stimulants.